These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 25976766)

  • 1. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
    Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
    Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
    Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.
    Kim HS; Hong M; Lee SC; Lee HY; Suh YG; Oh DC; Seo JH; Choi H; Kim JY; Kim KW; Kim JH; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Eur J Med Chem; 2015 Nov; 104():157-64. PubMed ID: 26457742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
    Oh SH; Woo JK; Yazici YD; Myers JN; Kim WY; Jin Q; Hong SS; Park HJ; Suh YG; Kim KW; Hong WK; Lee HY
    J Natl Cancer Inst; 2007 Jun; 99(12):949-61. PubMed ID: 17565155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
    Lee HJ; Min HY; Yong YS; Ann J; Nguyen CT; La MT; Hyun SY; Le HT; Kim H; Kwon H; Nam G; Park HJ; Lee J; Lee HY
    Theranostics; 2022; 12(1):105-125. PubMed ID: 34987637
    [No Abstract]   [Full Text] [Related]  

  • 8. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
    Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
    Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
    Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
    Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
    Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
    Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
    Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models.
    Zhang Q; Zhai S; Li L; Li X; Zhou H; Liu A; Su G; Mu Q; Du Y; Yan B
    Biochem Pharmacol; 2013 Aug; 86(3):351-60. PubMed ID: 23743233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding.
    Lee SH; Jee JG; Bae JS; Liu KH; Lee YM
    J Cell Physiol; 2015 Apr; 230(4):853-62. PubMed ID: 25204544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
    Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
    Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
    Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.
    Yao H; Xu F; Wang G; Xie S; Li W; Yao H; Ma C; Zhu Z; Xu J; Xu S
    Eur J Med Chem; 2019 Apr; 167():485-498. PubMed ID: 30784881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.